

(12) **UK Patent Application** (19) **GB** (11) **2 221 843** (13) **A**
(43) Date of A publication 21.02.1990

(21) Application No 8917711.7

(22) Date of filing 02.08.1989

(30) Priority data
(31) 8819110 (32) 11.08.1988 (33) GB

(71) Applicant
Norsk Hydro a s

(Incorporated in Norway)

Bygdøy Allé 2, 0257 Oslo 2, Norway

(72) Inventors
Hans Einar Krokan
Kaare H. Bønna
Harald Brelvik
Bernt Børretzen
Knut Helgas Dahl

(74) Agent and/or Address for Service
Lloyd Wise Tregear & Co
Norman House, 105-109 Strand, London, WC2R 0AE,
United Kingdom

(51) INT CL⁴
A61K 31/20

(52) UK CL (Edition J)
A5B BJA B180 B26Y B401 B406
U1S S2415

(56) Documents cited
GB 2197199 A GB 2148713 A EP 0283140 A2
EP 0175468 A2 WO 87/02247 A1
Acta. Toxicol. Ther., Vol.8 (3), Pages 339-352

(58) Field of search
UK CL (Edition J) A5B BHA BJA BJB BJC
INT CL⁴ A61K
Online Databases: CAS online, WPI

(54) **Omega-3-fatty acid composition**

(57) Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5, 8, 11, 14, 17-eicosapentaenoic acid (EPA) and (all-Z)-4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) comprise at least 75% by weight of the total fatty acids and are in a ratio of 1:2 to 2:1. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.

GB 2 221 843

FATTY ACID COMPOSITION

Present invention relates to a fatty acid composition comprising at least 80% by weight of omega-3 polyunsaturated fatty acids, wherein at least 75% by weight of the total fatty acids comprise omega-3 (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) C 20:5 and (all-Z)-4,7,10,13,16,29-docosahexaenoic acid (DHA) C 22:6.

Field of Invention

Cardiovascular diseases leading to morbidity and premature mortality is related to several risk factors such as hypertension, hypertriglyceridemia, hypercholesterolemia, high blood platelet aggregation and according to recent findings, a high activity of the blood coagulation factor VII phospholipid complex. Over the last three decades antihypertensive drugs have contributed to the decline in cardiovascular disease-related morbidity and mortality. There is however heightened concern about side effects and toxicity associated with the current antihypertensive therapy, especially in the mild hypertensive patient. There are results indicating that although the presently used antihypertensive agents are efficient in reducing blood pressure the pulse rate is coincidentally enlarged. Thus there is a need for a drug with fewer adverse effects for the treatment of hypertension. It would be particularly advantageous if such a drug could be used for the simultaneous treatment of all the above mentioned mul-

multiple risk factors associated with cardiovascular diseases, which is generally not the case with the currently available antihypertensive drugs.

Description of prior art

During the last decade numerous publications have appeared which report that various dietary fish oil preparations containing omega-3 polyunsaturated fatty acids have an effect on serum cholesterol and blood platelet aggregation. The mechanisms suggested for these effects often centre around the prostanoid system. Thus there is some information on how dietary fish oils alter the excretion of some prostaglandin metabolites but available data conflict on several points.

A reduction of blood pressure has been reported after intake of fish, crude fish oil (starting at 7% EPA and 5% DHA) or slightly concentrated fish oil preparations (typically containing 18% EPA and 12% DHA) although the components responsible for these effects were never identified. Furthermore all the studies presented so far had one or more serious flaws as pointed out in reviews of the available studies [H.R.Knapp et al., Proceedings of AOCS Short Course on polyunsaturated Fatty Acids and Eicosanoids, Ed. W.E.M. Lands, pp.41-55, American Oil Chemists Society] and [K. Bønaa, Tidsskr. Nor Lægeforen nr. 28, 1987, 2425-8].

Eicosapentaenoic acid C 20:5 omega 3 (EPA) has been considered to be the most important of the marine omega-3 polyunsaturated fatty acids partly because of its potent antiaggregatory action i.a. reported in US Patent No. 4,097,602, Silver et al, which was filed in August 1974. Later Dyerberg et al also described the same effect in [Lancet, p.152, Jan.21, 1978] and [Lancet II, p 117-119, July 15, 1978]. The main reason for the assumed importance of EPA is probably that it belongs to the eicosanoids which are key substances for the prostaglandin metabolism.

However according to several recent reports EPA alone does not have a significant effect on hypertension. In "Effects of highly purified eicosapentaenoic acid to angiotensin II and norepinephrine in the rabbit", [Prostaglandins August 1986, Vol. 32, No 2, pp 179-187] no reduction to blood pressure in rabbits was obtained using highly purified EPA of 90% concentration. Terano et al, [Atherosclerosis, 46, 321-331, (1983)] reported that a preparation containing 75% EPA and 6.2% DHA had no significant effect on blood pressure in healthy volunteers after an intake of 3.6 g EPA ethyl ester. Similarly, Yoshida et al, [Artery, 14, 295-303, 1987], reported no effect on basal blood pressure after intake of 900mg EPA ethyl ester for 14 days or more. Furthermore 90% EPA methyl ester had no effect on spontaneously hypertensive rats [K. Yin et al, 1988, Clinical and Experimental Pharmacology and Physiology 15, 275-280].

In contrast to this, British patent application 2197199 describes a composition for combatting pregnancy-induced hypertension where the compositions used in the example had an EPA content of 28-35%. The patients had no earlier history of hypertension. Hypertension being developed under pregnancy is considered to have different biological causes than normal hypertension, which seems to be underlined by the fact that it usually disappears after the termination of the pregnancy.

To our knowledge there is nothing to suggest that DHA alone has any effect on the blood pressure.

According to US patent 3,082,228 based on an application filed Dec.18, 1959 a product containing at least 60% polyunsaturated fatty acids having 20 C atoms or more lowers the blood cholesterol content significantly. Although other early studies indicate that fish oils lower total cholesterol and LDL-cholesterol and raises HDL-cholesterol later results have generally drawn the opposite conclusion as pointed out by W.S.Harris in [(n-3)news, 3 (4), 1-7]. Thus when summarizing 45 articles on

the subject, he found that LDL-cholesterol was increased by 2-30% depending on the type of hyperlipidaemia.

From PCT/WO 87/02247 is known a lipid emulsion for parenteral use comprising an emulsifier, water and a marine oil comprising at least one omega-3 fatty acid wherein the concentration of the free fatty acid in the emulsion is below about 5 meq/l, and wherein the marine oil will contain at least 30% by weight of a combination of esters of EPA and DHA. This lipid emulsion is used for the intravenous treatment of thrombotic disease states.

Summary of the invention

It has now been found that fatty acid compositions containing a high concentration, of at least 80 % by weight, of omega-3 fatty acids, salts or derivatives thereof, where EPA and DHA are present in relative amounts of 1:2 to 2:1, and constitute at least 75% of the total fatty acids, has a surprisingly advantageous effect on all the above mentioned risk factors for cardiovascular diseases, but especially a good effect on mild hypertension, hypertriglyceridemia and on the coagulation factor VII phospholipid complex activity. It lowers serum LDL-cholesterol, increases serum HDL-cholesterol, lowers serum triglycerides, lowers systolic and diastolic blood pressure and the pulse rate and lowers the activity of the blood coagulation factor VII-phospholipid complex. Although the detailed biological mechanisms for the effects of the compositions according to present application are not explicitly known, there are indications of a surprising synergism between the action of EPA and of DHA.

One advantage of the compositions according to present application is their being very well tolerated, not giving rise to any severe side effects.

An especially preferred composition according to present

application comprises at least 90% by weight of long chain, polyunsaturated omega-3 fatty acids of which EPA and DHA constitute at least 85% by weight of the total fatty acids and are present in a ratio of EPA:DHA from 1:1 to 2:1 especially about 3:2.

In order to isolate EPA and DHA in a mixture of high concentration according to present application, a special method was developed for purifying and isolating the long chain fatty acids from natural fish oils. Compositions according to present application may be produced according to the method of our European Patent Application No.86906964.1. The analysis in % by weight was based on the ethyl esters even if other derivatives or salts or the acids themselves are a part of the present invention.

Detailed Description of the Invention

The composition according to this invention is preferably produced via the following method. Initially the marine oil raw material is esterified and concentrated via urea fractionation or the like, where the conditions are sufficiently mild to avoid disintegration of the products. The second stage is a molecular distillation.

The fractionation in principle initially removes the major part of the esters having chain length below C 20. Thereafter a main fraction is removed consisting essentially of esters of the C 20- and C 22 acids. As the urea fractionation removes the saturated and less unsaturated esters, this fraction will contain high concentrations of EPA and DHA, according to the present method at least 75% by weight. The total amount of the long chain omega-3 acids will be at least 80% by weight. Other preferred compositions according to present application contain at least 95% by weight, with the EPA plus DHA content being at least 90% by weight. Another preferred composition according to present application contains at least 85% by

weight of the total omega-3 fatty acids and an EPA and DHA amount of at least 80% by weight.

Other omega-3 acids of the C 20, C 21 and C 22 series will be obtained approximately in their original concentrations, e.g. from 3-5% by weight, typically at least 4.5% by weight. Thus the special and odd-numbered omega-3 all-Z 6, 9, 12, 15, 19 - heneicosapentaenoic acid C 21:5 is normally present in concentrations of at least 1.5% by weight and omega-3 all-Z 7,10,13,16,19-docosapentaenoic acid normally in concentrations of about 3.0% by weight.

After removing the urea precipitate, the solvent used, normally ethanol, is partially or fully removed by evaporation and the esters thus isolated may be further purified by washing with water or a slightly alkaline water solution if the pure esters without contamination of the acids should be isolated.

The free acids may be produced by well known hydrolyzation procedures.

The upgrading of the EPA fraction to obtain a weight ratio of EPA:DHA of from 1:1 to 2:1, especially 3:2 or the upgrading of the DHA fraction to obtain a EPA:DHA weight ratio of from 1:1 to 1:2 may be achieved in the molecular distillation stage. The method also provides the possibility of using supercritical fluid extraction and/or chromatography in the second stage with CO₂ eventually containing a more polar modifier, such as ethanol, in order to concentrate the EPA and/or DHA fraction.

The urea fractionation and the subsequent molecular distillation are performed under gentle conditions to avoid oxidation and/or isomerisation of the highly unstable omega-3 acids. As seen from Table 1 and 2 below, which gives the analysis of products obtained in accordance with the method of this invention, there was not more than 1% of unknown components

in the purified product. There are, however, a certain amount of minor products such as C-16 and C-18 acids as will appear from the detailed analysis shown in Table 2.

For the main part these products will be the combined sum of the fraction of fatty acid esters, which are naturally occurring in fish oils, but the concentration of each separate ester in the finished product is less than 0.2%, apart from the omega-3 octadecatetraenoic acid C 18:4 n-3, which is present in approximately the same amount as in the starting material.

Thus it will be understood that the total concentration of by-products occurring from the process is very low.

The process is flexible enough to affect the relative proportions between the long chain C 20, C 21 and C 22 fatty acids which occur naturally in available fish oil raw materials. It provides not only for the upgrading of the individual acids, but the ratio between them will remain within a pattern of variation which is optimal in nature. But simultaneously there is room for compensating the sometimes extreme variations which may occur naturally, cfr. below. Thus it will be possible to make a product with a constant and predetermined composition.

Fish oils may also contain by-products and contaminants such as pesticides, chlorinated hydrocarbons, heavy metals, cholesterol and vitamins. During the production of the concentrate, the concentrations of these components are significantly reduced compared to untreated fish oils.

In nature the relative contents of EPA and DHA, and also of the other long chain omega-3 acids, is dependent on the marine species and there are also seasonal variations within the same species. In the USA fish oil is today mainly produced from menhaden. This oil will typically contain 14-19% EPA and 5-8% DHA. Our analysis of one cod liver oil batch showed a content

of 6.9 EPA and 8.4 DHA. For capelin the EPA values varied from 8.6 to 11.4 from January 1973 to August 1973, while the DHA values from 6.7% to 11% during the same period. For Norwegian coastal herring the content in October 1973 was 6.4% EPA and 9.8% DHA, while catches in November 1983 showed a reduction to 1.7% and 1.1%, respectively.

These variations mean that dietary intake of fish oils or fish alone, will not secure a constant supply of omega-3 acids. Even if all the long chain C 20, C 21 and C 22 omega-3 acids will not or only may become moderately upgraded during the process, they will be preserved at least in their original proportions.

In Table 1 the left hand column illustrates the typical variations between the contents of individual long chain acids in the compositions of this invention, while the right hand column shows the exact analysis of the test sample used in the study on the biological effects, the results of which are shown in the Tables 4-8 below.

Table 1

	Typical product variation	Test Sample
C 20:4 omega-6	1- 2	1,4
C 20:5 omega-3	40-60 wt %	54 wt %
C 21:5 omega-3	1- 4 "	1,5 "
C 22:5 omega-3	1- 3 "	2 "
C 22:6 omega-3	25-45 "	32,6 "
lower acids	3- 8,5 "	7,5 "
unknown	1 "	1 "
sum Omega-3 FA		90.1 "
sum EPA + DHA		86.6 "
EPA : DHA		3.3 : 2

Table 2 shows a detailed analysis of a batch of starting material and of another composition of this invention obtained therefrom.

Table 2

<u>Fatty acid composition (%)</u>		
<u>Fatty acid</u>	<u>Starting material Fish oil,</u>	<u>Product ethyl ester test sample</u>
C14:0	7.6	0.0
Pristanate	0.4	0.0
C16:0	19.1	0.0
C16:1 n7	7.2	0.0
7-Me16:0	0.3	0.0
C16:2 n6	0.5	0.0
C16:2 n4	1.2	0.0
Phytanate	0.3	0.0
C16:3 n4	0.5	0.0
C16:4 n1	1.0	0.2
C18:0	2.3	0.0
C18:1 n9	9.1	0.0
C18:1 n7	3.0	0.0
C18:1 n5	0.4	0.1
C18:2 n6	1.1	0.0
C18:2 n4	0.2	0.0
C18:3 n6	0.2	0.2
C18:3 n3	0.7	0.2
C18:4 n3	2.5	2.8
C18:4 n1	0.1	0.2
C20:1 n9+7	5.9	0.0
C20:1	0.1	0.0
C20:2 n6	0.2	0.1
C20:3 n6	0.1	0.0
C20:4 n6	0.7	1.4
C20:4 n3	1.2	0.9
C20:5 n3	16.5	53.4
C22:1 n11+9	4.6	0.0
C22:2 n6	0.7	0.0
C21:5 n3	0.9	1.6
C22:4 n6	0.1	0.0
C22:5 n6	0.1	0.4
C22:5 n3	2.0	3.1
C22:6 n3	7.9	34.3
Sum unknown	1.0	1.0
Sum omega-3 FA	31.7	95.4
incl. C 18	3.2	3.0
Sum EPA +DHA	24.4	87.7
EPA : DHA	2.1 : 1	3.1 : 2

Table 3 shows the main fatty acid contents of several compositions according to present application.

Table 3

Fatty acid	Composition (%)					
C18:2 n6	0.3	0.3	0.1	0.0	0.2	0.1
C18:3 n3	0.3	0.3	0.0	0.1	0.3	0.0
C18:4 n3	2.3	2.3	3.6	2.2	1.8	0.7
C18:4 n1	0.2	0.2	0.4	0.3	0.0	0.0
C20:4 n6	1.7	1.7	1.5	3.9	1.6	1.6
C20:4 n3	2.4	0.9	1.3	1.2	1.9	0.3
C20:5 n3	54.7	52.7	42.2	48.5	41.0	31.7
C21:5 n3	2.1	2.1	1.7	2.0	1.7	1.2
C22:5 n6	0.4	0.4	0.6	0.8	0.7	1.1
C22:5 n3	5.4	5.8	2.8	4.3	5.8	3.3
C22:6 n3	28.7	31.0	38.0	34.9	42.4	58.5
Sum n3FA	95.9	95.1	89.6	93.2	94.9	95.7
incl. C 18						
Sum EPA+DHA	83.4	83.7	80.2	83.4	83.4	90.2
EPA : DHA	1.9:1	1.7:1	1.1:1	1.4:1	1:1	1:1.8

n3FA denotes omega-3 fatty acids

BIOLOGICAL EFFECTS.

In order to evaluate the effect of a composition according to present application on blood pressure, pulse rate, triglyceride levels, serum cholesterol and HDL-cholesterol, blood platelet aggregation and the coagulation factor VII phospholipid complex activity, the whole population aged 34-60 years, of a small Norwegian town was invited to a health check and of those, 22000 persons were screened for the following criteria:

- untreated moderate hypertension of a diastolic blood pressure (DBP) ranging from 89 to 111 mm Hg and a systolic blood pressure (SBP) from 110 to 180 mm Hg.
- no previous cardiac illness and not using cardiac drugs
- no severe diseases
- not extremely overweight

- no alcoholism
- serum cholesterol of at least 6.0 mmol/liter

The group of volunteers selected by these criteria amounted to 172 persons. The volunteers were screened during a run-in period of 6 month to ensure stabilization of blood pressure before the test substance was administered.

All blood pressure measurements were done with an automatic instrument (Dinamap) and at each occasion three measurements (with 2 minutes intervals) were done sitting and standing under controlled conditions. The average of the two last sitting and standing measurements were used.

The study was a controlled double blind one. The 172 volunteers were randomized to two groups of similar size. One group was treated with placebo capsules of corn oil, each with 1 g corn oil added 0.3% Vitamin E. The other group received capsules containing 1 g of the test substance whose composition is given in Table 1. Both sets of capsules were made of coloured soft gelatin to assure the blind effect. The volunteers were asked to take 3 capsules twice daily of either the test or control substance for 11 to 12 weeks. 171 volunteers completed the study and on average about 90% of the capsules were taken.

As will appear from tables 4 and 5 below, corn oil had no statistically significance effect on the blood pressure. The effect on the test substance on blood pressure was assessed first on the whole group taking the test substance and next on those individuals with higher blood pressures. The average blood pressures for the patients with higher blood pressures at the start and finish of the treatment with the active test substance of this invention are given in Table 4 (diastolic blood pressure) and Table 5 (systolic blood pressure).

Table 4

EFFECT OF TEST SUBSTANCE AND CORN OIL
ON DIASTOLIC BLOOD PRESSURE

DBP Range	Number of patients	Average DBP before treatment (mm HG)	Average DBP after treatment (mm Hg)	Average Reduction in DBP (mm Hg)	Signifi- cance
<u>Test substance</u>					
85-109	62	95.8	93.4	2.4	p<0.05
98-109	22	102	96.2	5.8	p<0.01
<u>Corn oil</u>					
85-109	57	95.7	96.0	0	n.s.
98-109	26	101.8	100.7	1.1	n.s.

n.s. means not significant

Table 5

EFFECT OF TEST SUBSTANCE AND CORN OIL
ON SYSTOLIC BLOOD PRESSURE

SBP of patients (mm Hg)	Number of patients	Average SBP before treatment (mm HG)	Average SBP after treatment (mm Hg)	Average Reduction in SBP (mm Hg)	Signifi- cance
<u>Test substance</u>					
> 135	71	148.1	144.5	3.6	p<0.05
> 150	24	158.4	150.3	8.1	p<0.001
> 155	15	162.2	152.4	9.8	p<0.001
<u>Corn oil</u>					
> 135	62	148.5	149.6	0	n.s.
> 150	23	159.1	158.0	1.1	n.s.
> 155	17	161.8	159.6	2.2	n.s.

As is evident from the above tables, the test substance had a highly significant hypotensive effect both on systolic and diastolic blood pressure. It is also clear that the effect is

strongest on those patients with the highest blood pressure. No significant effect was obtained in the corn oil group.

Table 6

EFFECT OF TEST SUBSTANCE AND CORN OIL
ON SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
ACCORDING TO DIETARY INTAKE OF FISH (DISHES PER WEEK)

Dishes per week	Number of patients		Average BP before treatment (mm HG)	Average BP after treatment (mm Hg)	Average Reduction in BP (mm Hg)	Signifi- cance
<hr/>						
Test substance						
0-2	44	SBP	145.3	139.3	-6.9	p=0.005
		DBP	99.8	94.0	-5.7	p=0.0001
3-5	34	SBP	143.6	141.2	-2.4	p=0.2
		DBP	97.7	96.3	-1.4	p=0.2
<hr/>						
Corn oil						
0-2	34	SBP	145.2	146.8	+1.6	p=0.4
		DBP	98.3	100.2	+1.9	p=0.1
3-5	44	SBP	142.3	143.4	+1.1	p=0.5
		DBP	97.4	97.9	+0.5	p=0.7

As appears from Table 6 a good hypotensive effect is achieved with the composition according to present application, surprisingly so even in the group with a high dietary intake of fish of 3-5 dishes per week. In comparison, no beneficiary effect is achieved with corn oil.

The results shown above indicates that a composition according to present application gives a surprisingly much better effect than a dietary intake of fish or slightly concentrated maine oil would lead to expect. This is probably due to a synergistic effect of EPA and DHA.

Compared with the test results achieved in the previously conducted studies with a dietary intake of marine fish oils,

the results achieved with a composition according to present application show a surprising improvement in effect on diastolic and systolic bloodpressure of slightly hypertensive patient respectively the more hypertensive patient of approximately 30% and 45%.

Table 7

EFFECT OF TEST SUBSTANCE AND CORN OIL
ON PULSE RATE (per minute)

Group	Before	After	Change	Significance
Test subst				
sitting	75.4	73.2	-2.2	p<0.02
standing	82.9	80.2	-2.7	p<0.005
Corn Oil				
sitting	74.3	75.1	+0.8	p=0.3
standing	80.9	82.2	+1.3	p=0.2

The pulse rate study included 78 persons in the group receiving the test substance and 77 persons in the other group.

As will appear from the Table above there was obtained a significant lowering in pulse rate with the test substance according to present application and a slight not significant raise of pulse rate with corn oil.

Table 8

EFFECT OF TEST SUBSTANCE AND CORN OIL
ON SERUM CHOLESTEROL [mmol/liter]

GROUP	BEFORE		AFTER	
	Tot.chol.	HDL Chol.	Tot.Chol.	HDL Chol.
<u>All Patients:</u>				
Test substance (n=78)	6.58	1.35	6.57	1.41**
Corn oil (n=78)	6.68	1.33	6.64	1.41**
<u>Tot. Chol.>7</u>				
Test substance (n=26)	7.74	1.53	7.31**	1.58*
Corn oil (n=20)	7.66	1.26	7.45*	1.32*

* p< 0.1

** p< 0.01

As appears from Table 8 the test composition according to present application lowers total serum cholesterol significantly in patients with a total cholesterol of above 7.0 mmol/liter and raises HDL cholesterol significantly in the whole population. Similar, but weaker effects are obtained in the corn oil group.

The compositions according to present application further lowers LDL-cholesterol by 5-10% in patients with total cholesterol > 7mmol/l but has no significant effect in patients with an total cholesterol of < 6.5mmol/l.

Table 9

EFFECT OF TEST SUBSTANCE AND CORN OIL ON SERUM TRIGLYCERIDE

<u>Triglyceride (mmol/l)</u>					
Group	n	Before	After	Reduction	p-value
TEST SUBSTANCE	87	1.51	1.20	0.31	0.001
CORN OIL	85	1.57	1.47	0.03	NS

Patients with triglycerides > 2.00 mmol/l

Group	n	Before	After	Reduction	p-value
TEST SUBSTANCE	14	3.28	2.03	1.25	0.0001
CORN OIL	17	3.22	2.66	0.56	0.01

As appears from Table 9 the test substance has the effect of lowering the level of serum triglycerides especially in patients with high levels (>2.0mmol/l) before treatment. No significant effect is obtained with corn oil in the whole group of volunteers, whereas a very small effect is obtained in persons with high levels of triglycerides.

Table 10EFFECT OF TEST SUBSTANCE AND CORN OIL
ON BLOOD PLATELET AGGREGATION

Group	n	Collagen 0,2 ug/ml				Collagen 0,1 ug/ml			
		Before		After		Before		After	
		\bar{X}	SEM	\bar{X}	SEM	\bar{X}	SEM	\bar{X}	SEM
TEST SUBST	21	63.4 \pm 4.40		38.8 \pm 5.19		38.0 \pm 5.91		13.7 \pm 3.77	
CORN OIL	21	73.5 \pm 4.40		57.4 \pm 6.37		43.4 \pm 45.5		15.2 \pm 3.32	

As will appear from Table 10, the compositions according to present application have a blood platelet antiaggregating effect.

The coagulation factor VII-phospholipid complex is found in the plasma from men belonging to a high risk group for cardiovascular diseases, as described in P.Leren et al, [The Oslo Study, Cardiovascular diseases in middle aged and young Oslo men. Acta Med. Scand. suppl.588, 1-38, (1987)] and Dalaker et al, [A novel form of factor VII in plasma from men at risk for cardiovascular disease, Br.J. Haematol., 61, 315-322, (1985)], and is considered to be another risk factor for cardiovascular disease.

Table 11EFFECT OF TEST SUBSTANCE AND CORN OIL
ON COAGULATION FACTOR VII PHOSPHOLIPID COMPLEX
ACTIVITY (PER CENT)

Group	n	Before	After	Difference
TEST SUBST	69	9.7	6.6	3.1 **
CORN OIL	72	8.5	8.8	0.3 N.S.

** $p < 0.02$

As appears from the table the activity is reduced significantly with the composition according to present application, whereas no significant effect is reached with corn oil.

According to the results shown in the tables 3-11 above, a composition according to present application has a significant effect on all the above mentioned risk factors for cardiovascular diseases. In comparison some positive results are obtained with corn oil but no significant effect is obtained for blood pressure, the level of serum triglycerides or for the activity of the coagulation factor VII. Further the effects measured in the corn oil group for these risk factors seem to be going in the opposite direction, being detrimental.

Thus fatty acid compositions according to the present invention are potentially valuable for the treatment and prophylaxis of multiple risk factors known for cardiovascular diseases, such as hypertension, hypertriglyceridemia and high coagulation factor VII phospholipid complex activity.

The doses of the composition of this invention needed for therapeutic or prophylactic effect will vary with the type of administration. In our large scale tests we administered 6 grams per person per day of the test composition. Generally for the average adult person the doses may vary from 1.0 to 10 grams depending upon body size and the seriousness of the condition to be treated.

The compositions according to present application may further be used as an additional drug to the customary hypertensive drug in treatment of hypertension. The doses will presumably lie in the lower part of the above mentioned dosage range.

Other possible medical indications for which the compositions according to present application may be administered are chronic polyarthrititis, psoriatic artheritis, periarteritis nodosa, lupus erythematosus disseminatus (LED), sclerodermia,

Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis and migraine as has been indicated in standard in vivo tests.

Perferably the active compounds should be orally administered in the form of pills, soft capsules or the like. However, the administration could also be through any other route where the active ingredients may be efficiently absorbed and utilized, e.g. intravenously, subcutaneously, rectally, vaginally or possibly topically.

The pharmaceutical composition may eventually comprise, in addition to the EPA and DHA active ingredients as defined, one or more pharmaceutically acceptable carrier as well known in the art. The compositions can also include fillers, stabilizers, extenders, binders, humidifiers, surfactants, lubricants and the like, as known in the art of formulating pharmaceutical composition.

In addition antioxidants, for example hydroxytoluene, butyrate, quinone, tocopherol, ascorbic acid etc., preservatives, colouring agents, perfumes, flavourings and other pharmaceutical agents may be used.

EXAMPLE OF PHARMACEUTICAL PREPARATIONSoft gelatine capsules containing 1g/per capsule

Composition:

EPA ethyl ester	525	mg/capsule
DHA ethyl ester	315	mg/capsule
d-alpha Tocopherol	4	IU/capsule
Gelatine	246	mg/capsule
Glycerol	118	mg/capsule
Red iron oxide	2.27	mg/capsule
Yellow iron oxide	2.27	mg/capsule

The active ingredients and the excipients are weighted and homogenized on a high speed stirrer. The mixture is then colloid milled and deaerated in a stainless steel vessel ready for encapsulation. The mixture is filled in soft gelatine capsules of size 20 oblong, (average weight 1.4g) using a standard capsulation machine.

Claims

1. Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, whereof (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) C 20:5 and (all-Z)-4,7,10,13,16,19-docosaenoic acid (DHA) C 22:6 are present in relative amounts of from 1:2 to 2:1 and constitute at least 75% by weight of the total fatty acids.
2. Composition according to claim 1, wherein other long chain fatty acids present are (all-Z C 21:5)-6,9,12,15,18-heneicosapentaenoic acid, and/or (all-Z C 22:5)-7,10,13,16,19-eicosahexaenoic acid and/or (all-Z C 18:4)-6,9,12,15-octadecatetraenoic acid.
3. Composition according to claim 1 or claim 2, wherein the total concentration of long chain omega-3 fatty acids is at least 90% by weight, whereof EPA and DHA constitute at least 85% by weight of the total fatty acids and are present in relative amounts of EPA:DHA from 1:1 to 2:1, especially about 3:2 and the other long chain omega-3 C 20, C 21 and C 22 acids constitute at least 4.5% by weight.
4. Composition according to claim 1, wherein the total concentration of long chain omega-3 fatty acids is at least 95% by weight, where EPA and DHA constitute at least 90% by weight of the total fatty acids and the other long chain C 20, C 21 and C 22 acids constitute at least 4.5% by weight.
5. Composition according to claim 1 or claim 2 wherein the total concentration of long chain omega-3 fatty acids is at least 85% by weight, where EPA and DHA constitute at least 80% by weight and the other long chain C 20,

C 21 and C 22 acids constitute at least 4.5% by weight.

6. Composition according to claim 4 or 5 wherein EPA and DHA are present in relative amounts of from 1:1 to 2:1.
7. Composition according to claim 1 wherein the fatty acids are present in the form of pharmaceutically acceptable salts.
8. Composition according to claim 1 wherein the fatty acids are present in the form of derivatives.
9. Composition according to claim 8 wherein the derivative is an ester, especially an alkyl ester.
10. Composition according to claim 9 wherein the fatty acids are present in the form of ethyl esters.
11. Composition according to any of the above claims for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
12. Method for the production of a fatty acid composition according to any of the claims 1-10, wherein main raw material is subjected to the following steps in optional sequence: transesterification, concentration via urea fractionation or the like, molecular distillation and/or supercritical fluid extraction or chromatography, whereby a main fraction consisting essentially of esters of the omega-3 C 20:5 and C 22:6 acids is isolated giving a total amount of long chain omega-3 fatty acid esters of at least 80% by weight, the urea fractionation and the molecular distillation being carried out under gentle conditions to avoid oxidation and isomerisation of the omega-3 acids.

13. Use of marine oil concentrate containing at least 80% long chain omega-3 fatty acids or salts or derivatives thereof, where (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) C 20:5 and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA) C 22:6 are present in relative amounts of from 1:2 to 2:1 and constitute at least 75% by weight of the total long chain fatty acids, for the manufacture of a pharmaceutical preparation for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
14. Method for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases comprising administering a composition according to the claims 1-10 eventually in admixture with a pharmaceutically acceptable carrier.
15. A process for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases, comprising incorporating with a pharmaceutically acceptable carrier or diluent a marine oil concentrate containing at least 80% by weight of long chain omega-3 fatty acids or salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) C 20:5 and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA) C 22:6 are present in relative amounts of from 1:2 to 2:1 and constitute at least 75% by weight of the total fatty acids.